Research & Development

Publications

Disclaimer

Etripamil is an investigational new drug which is not approved for commercial distribution in the United States. The publications in this section are for educational purposes to discuss clinical data relating to the investigational new drug. Etripamil has not been shown to be safe and effective for FDA approval purposes.

Data from Pivotal Trials of Etripamil in PSVT

 

Self-administered Etripamil Nasal Spray Rapidly Terminated Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT): Analysis of Open-Label Treatment in the RAPID Study

Heart Rhythm 2024


Etripamil Nasal Spray: Data for Acute Rate Control in Atrial Fibrillation with a Rapid Ventricular Rate (AFib-RVR)

2024 Stanford BioDesign Arrhythmia Technologies Retreat


Analysis of Healthcare Resource Utilization in the NODE-303 Trial to Terminate Paroxysmal Supraventricular Tachycardia Episodes

ISPOR


NODE 303: Multi-Center, Multi-National, Open-Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia

The American College of Cardiology


Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results from the NODE-303 Open-label Study – ScienceDirect

The Journal of The American College of Cardiology


Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study

Journal of the American Heart Association


Self-administered Intranasal Etripamil Using a Symptom-prompted, Repeat-dose Regimen for Atrioventricular-nodal-dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial

The Lancet


Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients with Supraventricular Tachycardia

ISPOR


Self-administered Etripamilfor Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis fromthe RAPID Study

American Heart Association


First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

American Heart Association


Rationale For and Design ofa Multicenter, Placebo-controlled, Phase 3 Study to Assess Efficacy and Safety of Intranasal Etripamilforthe Conversion of Paroxysmal Supraventricular Tachycardia

American Heart Journal


HRS 22: Long-Term Outcomes of the NODE-302 Study | Dr James Ip

Heart Rhythm Society


Analysis of Clinical Outcomes in the NODE-301 Trial

American College of Cardiology


Additional Clinical Data of Etripamil in PSVT

 

Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings

EHRA


Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study

Heart Rhythm Society


Etripamil Nasal Spray Reduces Heart Rate in Patients with Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm

American Heart Association


Etripamil Nasal Spray for Acute Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Heart Rhythm Society


Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. Journal of the American College of Cardiology. 2018.

Journal of the American College of Cardiology


Clinical Data of Etripamil in Atrial-Fibrillation with Rapid Ventricular Response (AF-RVR)

 

A Multicenter, Phase 2, Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Symptomatic Atrial Fibrillation (ReVeRA-201)

Circulation: Arrhythmia and Electrophysiology


Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRa-201

American Heart Association


Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation

Heart Rhythm Society


Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster

Heart Rhythm Society


PSVT Disease Burden

 

Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia inthe United States.

Journal of Cardiovascular Electrophysiology


Trends in Healthcare Resource Use and Expenditures in Patients with Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States. 2021.

American Heart Journal


Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.

Journal of the American Heart Association


Healthcare Resource Use and Expenditures in Patients Newly Diagnosed with Paroxysmal Supraventricular Tachycardia. American Journal of Cardiology. 2020.

American Journal of Cardiology